Alexion Pharma surges 30% on AstraZeneca deal

Monday, 14. December 2020 16:57

Shares of Alexion Pharmaceuticals Inc. jumped more than 31% on Monday following the news that AstraZeneca PLC is set to acquire the company for $39 billion.

Alexion stocks soared 31.29% to sell for $158.92 per share at 10:52 am ET. Since the start of the year, the company's shares have advanced over 46%. On the other hand, AstraZeneca plunged 7.16% two minutes later, trading for £75.88 per share in London.

The American company is known for its development of Soliris, a drug used to treat the rare disorders atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH), as well as other research related to autoimmune diseases.

Related Links: Alexion Pharmaceuticals Inc.
Breaking the News / ND